2023 年第 4 期 第 18 卷

草酸艾司西酞普兰片对甲基苯丙胺依赖者稽延性戒断症状疗效的研究

Study on the efficacy of escitalopram oxalate tablets in the treatment of protracted withdrawal symptoms in methamphetamine dependent patients

作者：于媛媛张宪武吴学谦李浩军

英文作者：Yu Yuanyuan Zhang Xianwu Wu Xueqian Li Haojun

单位：内蒙古自治区第三医院（脑科医院）儿童青少年心理医学中心重症精神疾病治疗中心，呼和浩特010010

英文单位：Children and Adolescents Psychological Medical Center Severe Mental Disease Treatment Center Inner Mongolia Third Hospital (Brain Hospital) Hohhot 010010 China

关键词：甲基苯丙胺依赖；草酸艾司西酞普兰片；稽延性戒断症状

英文关键词：Methamphetaminedependence;Escitalopramoxalatetablets;Protractedwithdrawalsymptoms

• 摘要：

• 目的 探讨草酸艾司西酞普兰片对甲基苯丙胺（MA）依赖者稽延性戒断症状的疗效。方法 选取2019年1—11月内蒙古自治区第三医院收治的60例MA依赖者为研究对象，应用随机数字表法分为观察组及对照组，各30例。对照组以谷维素片治疗12周；观察组以草酸艾司西酞普兰片治疗12周。比较2组治疗前和治疗4、8、12周汉密尔顿抑郁量表(HAMD-24)、汉密尔顿焦虑量表(HAMA)评分及治疗前、治疗12周匹兹堡睡眠质量指数(PSQI)量表评分、社会功能缺陷筛选量表（SDSS）总分。观察2组治疗期间药物不良反应发生情况。结果 治疗4、8、12周，2组HAMD-24、HAMA评分均低于治疗前，且观察组均低于对照组，差异均有统计学意义（均P＜0.05）。治疗12周，2组PSQI量表、SDSS评分均低于治疗前，且观察组均低于对照组，差异均有统计学意义（均P＜0.05）。观察组与对照组治疗期间药物不良反应发生率比较［30.0%（9/30）比13.3%(4/30)］，差异无统计学意义（χ2=2.455，P=0.117）。结论 草酸艾司西酞普兰对MA依赖者戒断后产生的焦虑抑郁情绪与睡眠障碍的改善有积极作用，且在治疗4周后效果显著，随着治疗时间延长至12周，效果更为明显。

• Objective To study the efficacy of escitalopram oxalate tablets in the treatment of protracted withdrawal symptoms in methamphetamine (MA) dependent patients. Methods From January to November 2019, 60 MA dependent patients admitted to Inner Mongolia Third Hospital were selected as the research subjects. They were divided into observation group and control group by the random number table method, with 30 cases in each group. The control group was treated with oryzanol tablets for 12 weeks, and the observation group was treated with escitalopram oxalate tablets for 12 weeks. The scores of Hamilton Depression Scale (HAMD-24) and Hamilton Anxiety Scale (HAMA) were evaluated before treatment and at 4, 8 and 12 weeks of treatment. The scores of Pittsburgh Sleep Quality Index (PSQI) scale and Social Deficiency Screening Scale (SDSS) were evaluated before treatment and at 12 weeks of treatment. The adverse drug reactions in the two groups were observed during the treatment. Results At 4, 8 and 12 weeks of treatment, the scores of HAMD-24 and HAMA in both groups were lower than those before treatment, and the scores in the observation group were lower than those in the control group(all P＜0.05). At 12 weeks of treatment, the scores of PSQI scale and SDSS in both groups were lower than those before treatment, and the scores in the observation group were lower than those in the control group(all P＜0.05). There was no statistically significant difference between the observation group and the control group in the incidence of adverse drug reactions during treatment ［30.0%(9/30) vs 13.3%(4/30)］(χ2=2.455， P=0.117). Conclusions  Escitalopram oxalate has a positive effect on the improvement of anxiety, depression and sleep disorder in MA dependent patients after withdrawal. The effect is significant at 4 weeks of treatment, and the effect is more significant with the prolongation to 12 weeks.